Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F24%3A00080250" target="_blank" >RIV/00159816:_____/24:00080250 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00136498 RIV/65269705:_____/24:00080250

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/ijc.35062" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ijc.35062</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ijc.35062" target="_blank" >10.1002/ijc.35062</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients

Popis výsledku v původním jazyce

A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents. While dendritic cell-based vaccines have emerged as one of the promising and well-tolerated immunotherapy options for cancers, most studies have been conducted in adults. Using the N-of-1 approach in a real-world scenario, the authors demonstrate that personalized dendritic cell vaccine is an effective component of the multimodal individualized treatment for pediatric high-risk solid tumors, especially in less burdened or aggressive diseases. Immune checkpoint inhibitors acted synergistically with the dendritic cell vaccine. The findings support the use of dendritic cell-based immunotherapy in clinical practice, with early vaccine preparation and delayed application boosted by immunomodulatory agents.

Název v anglickém jazyce

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients

Popis výsledku anglicky

A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents. While dendritic cell-based vaccines have emerged as one of the promising and well-tolerated immunotherapy options for cancers, most studies have been conducted in adults. Using the N-of-1 approach in a real-world scenario, the authors demonstrate that personalized dendritic cell vaccine is an effective component of the multimodal individualized treatment for pediatric high-risk solid tumors, especially in less burdened or aggressive diseases. Immune checkpoint inhibitors acted synergistically with the dendritic cell vaccine. The findings support the use of dendritic cell-based immunotherapy in clinical practice, with early vaccine preparation and delayed application boosted by immunomodulatory agents.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

—

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Cancer

ISSN

0020-7136

e-ISSN

1097-0215

Svazek periodika

155

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

1443-1454

Kód UT WoS článku

001260796700001

EID výsledku v databázi Scopus

2-s2.0-85197461804